PASITHEA THERAPEUTICS CORP (KTTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.57-4.89%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Resolution of Nasdaq listing compliance issues: Nasdaq bid price $0.60 vs $1.00 target.
Pasithea Therapeutics has a new Chief Medical Officer with strong clinical experience. The company showed positive interim Phase 1 data for PAS-004 in advanced solid tumors. It is working on treatments for neurofibromatosis type 1 and MAPK pathway cancers. These developments could lead to future growth if trials succeed.
The company is loss-making with no revenue and negative EPS expected through 2027. It faces regulatory challenges including a Nasdaq delisting notice. Recent legal and regulatory events add risk. The stock has declined 14.5% from its high and shows no clear path to profitability.
The market expects continued losses and no revenue growth, with implied negative earnings growth over 3 to 5 years. Our view aligns with this cautious outlook given the company’s current financials and risks.
Breaks if: No advancement or negative trial results reported by end of 2026
Breaks if: EPS loss worsens beyond -$1.01 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
KTTA represents a speculative growth investment with a focus on early-stage clinical development. The current thesis state is cautious due to ongoing losses and regulatory risks, despite some positive sector momentum.
The market appears to price in a low level of fragility, suggesting that KTTA's current valuation is relatively cheap compared to its peers. However, the low model confidence indicates that expectations may not be firmly grounded.
Fundamentals are likely to remain under pressure, as the company continues to report operating losses and negative cash flow. Management's focus on addressing compliance issues and advancing clinical development is crucial, but recent performance has not shown significant improvement.
The long-term thesis hinges on the performance of sector bellwethers and KTTA's ability to navigate regulatory challenges. A favorable outcome in clinical development or improved sector conditions could enhance prospects, while continued losses and compliance issues could weigh heavily.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Delisting occurs or compliance not restored by end of 2026
In the next 1 to 3 years, KTTA's trajectory will depend on management's execution and external sector dynamics. Not investment advice.